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Changing Lives Through Research

On the Job
Chuck Rowland, MSN, CRNP
Chuck Rowland, MSN, CRNP, first came
to Jefferson in 1986 as a newly graduated
clinical perfusionist. Over the next 25
years, he worked in several states and
returned to Jefferson as a perfusionist
before pursuing a career in nursing. In
2007, he completed his BSN in Villanova
University’s accelerated nursing program
and continued his studies to earn his MSN
as an Adult Nurse Practitioner in 2010.
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Jefferson and Lankenau
Institute of Medical
Research Collaborate
on Cancer Research
Located along Philadelphia’s Main Line in
Wynnewood, Pa., the Lankenau Institute
for Medical Research (LIMR) aims to
advance health and well-being through
research to improve the detection and
treatment of disease; the rapid transfer
of new technology to the clinic; and
the training of the next generation of
scientists and physicians.
Founded in 1927, LIMR now has a
team of 120 – including 20 resident
faculty members – working to advance
its mission. Those investigators include
LIMR President and CEO George C.
Prendergast, PhD, who also serves as
editor in chief of Cancer Research, the
most highly cited journal in the field,
and Janet Sawicki, PhD, Professor, whose
work focuses on cancer nanotherapy
and related technologies.
In recent years, Drs. Prendergast
and Sawicki have been collaborating
successfully with the Jefferson Department
of Surgery on research related to
diagnosis and treatment of pancreatic
and ovarian cancers. As Jonathan Brody,
PhD, Director of the Division of Surgical
Research recalls, the relationship took
root in 2007, when Dr. Sawicki delivered a
presentation on cancer nanotherapy at the
monthly Surgical Research Seminar hosted
by the Division.

Published by Jefferson Digital Commons, 2012

Since then, Jefferson and LIMR have
co-authored multiple publications and
secured four nationally recognized
grants (including from NIH and the
American Cancer Society) worth roughly
a million dollars.
The grants have funded research on
predicting and optimizing the effect
of gemcitabine therapy in ovarian and
pancreatic cancers; using the HuR stress
response gene to enhance Gemcitabine
therapy; using HuR to combat
chemotherapeutic resistance in ovarian
cancer; and IDO2 targeting for pancreatic
cancer treatment. Early work seeding
the IDO2 collaboration was published
initially by the Jefferson-LIMR team in
the Journal of the American College of
Surgery in 2009.
“Both these collaborations are unique
and allow us to attack these tumors with
different strategies,” Dr. Brody says.
“Drs. Prendergast and Sawicki are the
only people in the world I could do this
particular work with, and luckily, they are
in our backyard.”
The collaboration has been beneficial to
the researchers at LIMR, as well: “I met
Dr. Brody not long after he moved to
Jefferson from Johns Hopkins with Dr.
Charlie Yeo’s team, when we were each

Since April 2011, Rowland has been
supporting Jefferson’s Division of
Cardiothoracic Surgery as an outpatient
nurse practitioner. More recently, he
assumed additional responsibilities
as director of the Smoking Cessation,
Counseling and Therapy (SCCT) Program,
for which he became a Certified Tobacco
Treatment Specialist.
What is the SCCT Program?
The SCCT Program is a relatively new
endeavor that began with the progressive
ideas and support of Scott Cowan, MD,
FACS, one of our thoracic surgeons. The
program’s goal is to jumpstart smoking
cessation prior to surgery. During the
appointment process, we screen all
patients for smoking. If the patient agrees,
we schedule him or her for a separate
appointment for smoking cessation planning.
We’ve designed the SCCT Program to
provide one-on-one counseling tailored
to individual patient needs. Each smoking
cessation plan of care is formulated with

just beginning to become interested in
how IDO2 may affect cancer,” recalls
Dr. Prendergast. “We had discovered this
gene as a result of our work in cancer
immunotherapy, but its connections to
pancreatic cancer would not have been
made so soon without Dr. Brody’s initial
observation that brought us together.”

“Drs. Prendergast and Sawicki
are the only people in the world
I could do this particular work
with, and luckily, they are in
our backyard.”
Dr. Sawicki feels similarly about the
interactions that started with the seminar
at Jefferson: “Jonathan and I quickly
identified a few high-impact questions
of common interest where our research
programs could readily benefit from
collaborative work,” she said. “We were
fortunate that the multidisciplinary

patient input. For most patients, the goal
is to quit smoking over a period of a few
weeks – and then sustain that success
over the long term.
What is your philosophy of patient care?
Patients are multidimensional. When they
come to us with physical issues, they
also bring social, cultural and spiritual
dimensions. I believe it’s important to
formulate a plan of care that incorporates
and adapts to these needs.
What most energizes you about
your career?
I’m energized by the ability to help patients
navigate through their journey with
cardiothoracic surgery and/or smoking
cessation, which for most is a very stressful
time. I always strive to help patients and
their families truly understand what’s
happening – from admission through final
discharge and even weeks after surgery.
Learn more at: www.jeffersonhospital.org/SCCT

synergies in the work we started were
welcomed so readily by the grant
review committees who have made its
development possible.
“For me, the ability to benefit from access
to clinical specimens and linked databases
was critical, given that few groups have
assembled such a valuable foundation
to enable research into the questions I
wished to pursue.”
Jefferson and LIMR are currently preparing
two grants for roughly $1.25 million each
from the NIH Research Project Grant
Program (R01). If awarded, these grants
will fund research targeting HuR and IDO
molecules for the treatment of pancreatic
cancer and ovarian cancers – which all
three investigators hope will be translated
to the clinic within the next few years.
For more information about the Division of Surgical
Research visit: www.jefferson.edu/surgery
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